Although TGF-β plays a paradoxical role in tumor development, recent studies have suggested that TGF-β signaling is essential for the development of bone metastasis, and TGF-β-directed therapies inhibit prostate cancer bone metastases63–65. Here, TGFB1 is linked to prostate carcinoma.